Inaxaplin for Proteinuric Kidney Disease in Persons with Two <i>APOL1</i> Variants

Abstract

Targeted inhibition of APOL1 channel function with inaxaplin reduced proteinuria in participants with two <i>APOL1</i> variants and focal segmental glomerulosclerosis. (Funded by Vertex Pharmaceuticals; VX19-147-101 ClinicalTrials.gov number, NCT04340362.).